Abingworth’s Transatlantic Reach
Even in the age of instant electronic communication, there is no substitute for face-to-face discussions and informal get-togethers. That’s why we have offices in key biotech hubs in both the US and Europe, so that we can interact more productively with the entrepreneurs we support. These offices also enable us to tap more effectively into the deep talent pools and scientific networks in and around those hubs.Meet the team
15 Life Science Funds
Abingworth has raised 15 funds dedicated to investing in life sciences and healthcare.
Our most recent venture fund, Abingworth Bioventures 8, raised $466 million while Abingworth’s Clinical Co-Development Fund 2 and Clinical Co-Development Co-Investment Fund raised $466 million and $356 million respectively. All are actively investing.
The funds invest in private and public companies across three broad strategic areas: seed and early stage, development stage (including VIPEs and public markets) and clinical co-development.